Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)

Background Atrial fibrillation (AF) adds significant risk of stroke and thromboembolism in patients on hemodialysis (HD). The aim of this study was to investigate the prevalence of AF in a population-based cohort of HD patients and practice patterns of antithrombotic therapy for stroke prevention in AF. Methods The Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemodialysis (VIVALDI), an ongoing prospective observational cohort study, investigates the prevalence of AF and the risk of thromboembolic events in HD patients in Vienna, Austria. We analyzed cross-sectional data of 626 patients (63.4% men, median age 66 years, approx. 73% of HD patients in Vienna), who provided informed consent. A structured interview with each patient was performed, recent and archived ECGs were viewed and medical histories were verified with electronic records. Results The overall prevalence of AF was 26.5% (166 patients, 71.1% men, median age 72 years) of which 57.8% had paroxysmal AF, 3.0% persistent AF, 32.5% permanent AF, and 6.6% of patients had newly diagnosed AF. The median CHA2DS2-VASc Score was 4 [25th-75th percentile 3–5]. In multivariable analysis, AF was independently associated with age (odds ratio: 1.05 per year increase, 95% confidence interval: 1.03–1.07), male sex (1.7, 1.1–2.6), history of venous thromboembolism (2.0, 1.1–3.6), congestive heart failure (1.7, 1.1–2.5), history of or active cancer (1.5, 1.0–2.4) and time on HD (1.08 per year on HD, 1.03–1.13). Antithrombotic treatment was applied in 84.4% of AF patients (anticoagulant agents in 29.5%, antiplatelet agents in 33.7%, and both in 21.1%). In AF patients, vitamin-K-antagonists were used more often than low-molecular-weight heparins (30.1% and 19.9%). Conclusions The prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF.

[1]  Ming-Ju Wu,et al.  Prediction of Mortality in Incident Hemodialysis Patients: A Validation and Comparison of CHADS2, CHA2DS2, and CCI Scores , 2016, PloS one.

[2]  A. Garg,et al.  The Risk of Major Hemorrhage with CKD. , 2016, Journal of the American Society of Nephrology : JASN.

[3]  K. Ogasawara,et al.  Standardized Prevalence Ratios for Atrial Fibrillation in Adult Dialysis Patients in Japan. , 2016, Journal of epidemiology.

[4]  D. Tarng,et al.  Risks of Death and Stroke in Patients Undergoing Hemodialysis With New-Onset Atrial Fibrillation: A Competing-Risk Analysis of a Nationwide Cohort , 2016, Circulation.

[5]  Jenny I. Shen,et al.  Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  Sudha Seshadri,et al.  50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study , 2015, The Lancet.

[7]  A. Santoro,et al.  Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  G. Lip,et al.  Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. , 2015, European heart journal.

[9]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[10]  T. Chao,et al.  Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage renal disease requiring dialysis. , 2014, Heart rhythm.

[11]  Jung-Der Wang,et al.  Risk of stroke in long-term dialysis patients compared with the general population. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[12]  J. Jukema,et al.  The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients , 2014, Heart.

[13]  J. Tu,et al.  Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis , 2014, Circulation.

[14]  J. Carrero,et al.  Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. , 2014, JAMA.

[15]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[16]  J. Spertus,et al.  Stroke and the "stroke belt" in dialysis: contribution of patient characteristics to ischemic stroke rate and its geographic variation. , 2013, Journal of the American Society of Nephrology : JASN.

[17]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[18]  F. Kronenberg,et al.  Coumarins and survival in incident dialysis patients. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  W. Winkelmayer,et al.  Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[20]  J. Spertus,et al.  Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  W. Winkelmayer,et al.  The increasing prevalence of atrial fibrillation among hemodialysis patients. , 2011, Journal of the American Society of Nephrology : JASN.

[22]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[23]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[24]  Jeroen J. Bax,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  P. Kerr,et al.  Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. , 2010, Kidney international.

[26]  Gregory Y H Lip,et al.  Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.

[27]  R. Thadhani,et al.  Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. , 2009, Journal of the American Society of Nephrology : JASN.

[28]  P. Castellano,et al.  Atrial fibrillation in incident dialysis patients. , 2009, Kidney international.

[29]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[30]  Maria Grazia Valsecchi,et al.  Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  A. Yıldırır,et al.  Frequency of atrial fibrillation and factors related to its development in dialysis patients. , 2006, International journal of cardiology.

[32]  F. Dekker,et al.  Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  M. Valsecchi,et al.  Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[34]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[35]  B. Kestenbaum,et al.  Elevated risk of stroke among patients with end-stage renal disease. , 2003, Kidney international.

[36]  J. Hirsh,et al.  Is impaired renal function a contraindication to the use of low-molecular-weight heparin? , 2002, Archives of internal medicine.

[37]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[38]  P. Balcke,et al.  Incidence of Stroke among Chronic Hemodialysis Patients with Nonrheumatic Atrial Fibrillation , 2001, American Journal of Nephrology.

[39]  R. Hart,et al.  Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention , 1999, Annals of Internal Medicine.